UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Is existing cervical cancer screening proven productive in developing nations: Time to move from the laboratory to community?

South Asian journal of cancer, 2013-10, Vol.2 (4), p.242-242

2013

Volltextzugriff (PDF)

Clinical and biochemical profile of Indians with type 2 diabetes mellitus: A problem lurking for India

Tropical journal of medical research, 2014-07, Vol.17 (2), p.91

2014

Volltextzugriff (PDF)

A Case of Acquired Ventricular Septal Defect Complicating Silent Myocardial Infarction: An Unusual Presentation

Heart India, 2015, Vol.3 (1), p.24-26

2015

Volltextzugriff (PDF)

A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105

Cancer discovery, 2019-03, Vol.9 (3), p.384-395

2019

Volltextzugriff (PDF)

Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer

Journal of thoracic oncology, 2015-12, Vol.10 (12), p.1670-1674

2015

Volltextzugriff (PDF)

A comparative study of efficacy and safety of azithromycin and ofloxacin in uncomplicated typhoid Fever: a randomised, open labelled study

Journal of clinical and diagnostic research, 2012-12, Vol.6 (10), p.1736-1739

2012

Volltextzugriff (PDF)

ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab-Paclitaxel in Patients with Advanced Solid Tumors

Cancer research communications, 2024-09, Vol.4 (9), p.2415-2426

2024

Volltextzugriff (PDF)

Initial results from a phase 1b study of ORIC-101, a glucocorticoid receptor antagonist, in combination with nab-paclitaxel in patients with advanced solid tumors

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.2553-2553

2021

Volltextzugriff (PDF)

A phase 1 dose escalation study of RXDX-105, an oral RET and BRAF inhibitor, in patients with advanced solid tumors

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.2574-2574

2016

Volltextzugriff (PDF)

Abstract C188: A phase 1 study of RXDX-105, an oral RET, BRAF and EGFR tyrosine kinase inhibitor, in patients with advanced or metastatic cancers

Molecular cancer therapeutics, 2015-12, Vol.14 (12_Supplement_2), p.C188-C188

2015

Volltextzugriff (PDF)

Abstract CT007: Entrectinib, an oral pan-Trk, ROS1, and ALK inhibitor in TKI-nave patients with advanced solid tumors harboring gene rearrangements: Updated phase I results

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.CT007-CT007

2016

Volltextzugriff (PDF)

Abstract CT007: Entrectinib, an oral pan-Trk, ROS1, and ALK inhibitor in TKI-naïve patients with advanced solid tumors harboring gene rearrangements: Updated phase I results

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.CT007-CT007

2016

Volltextzugriff (PDF)

Barriers to Restorative Care as Perceived by Patients Attending Government Hospitals in Udaipur, Rajasthan

Pesquisa brasileira em odontopediatria e clínica integrada, 2014-01, Vol.14 (1), p.13-16

2014

Volltextzugriff (PDF)

1 – 15 von 15

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(12)
Mit Volltextzugriff
(14)

Publikationsform

Artikel
(15)

Sprache

Englisch
(15)

Erscheinungsjahr

n.n

Kollektion

2 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Is existing cervical cancer screening proven productive in developing nations: Time to move from the laboratory to community?

Clinical and biochemical profile of Indians with type 2 diabetes mellitus: A problem lurking for India

A Case of Acquired Ventricular Septal Defect Complicating Silent Myocardial Infarction: An Unusual Presentation

Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)

A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105

Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer

A comparative study of efficacy and safety of azithromycin and ofloxacin in uncomplicated typhoid Fever: a randomised, open labelled study

ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab-Paclitaxel in Patients with Advanced Solid Tumors

Initial results from a phase 1b study of ORIC-101, a glucocorticoid receptor antagonist, in combination with nab-paclitaxel in patients with advanced solid tumors

A phase 1 dose escalation study of RXDX-105, an oral RET and BRAF inhibitor, in patients with advanced solid tumors

Abstract C188: A phase 1 study of RXDX-105, an oral RET, BRAF and EGFR tyrosine kinase inhibitor, in patients with advanced or metastatic cancers

Abstract CT007: Entrectinib, an oral pan-Trk, ROS1, and ALK inhibitor in TKI-nave patients with advanced solid tumors harboring gene rearrangements: Updated phase I results

Abstract CT007: Entrectinib, an oral pan-Trk, ROS1, and ALK inhibitor in TKI-naïve patients with advanced solid tumors harboring gene rearrangements: Updated phase I results

Safety and Antitumor Activity of the Multi-Targeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib (RXDX-101): Combined Results from Two Phase 1 Trials (ALKA-372-001 and STARTRK-1)

Barriers to Restorative Care as Perceived by Patients Attending Government Hospitals in Udaipur, Rajasthan

Suchergebnisse filtern